English | 简体中文 | 繁體中文 | 한국어 | 日本語
 Latest Press Releases
Friday, January 30, 2026
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
21:50 HKT/SGT
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
21:30 HKT/SGT
SuperX Commences Production at First Global Supply Center
19:24 HKT/SGT
Quam Plus Financial Proudly Serves as Gold Sponsor, The 3rd Hong Kong Capital Markets Forum 2026 Successfully Concludes
19:18 HKT/SGT
From Digitization to AI Computing: Cheche Group Inc. (CCG) Partners with Volkswagen DSSO and Cardif Airstar Insurance to Usher in the "Premium Era" of Advanced Smart Driving Insurance
18:35 HKT/SGT
Nissin Foods (Hong Kong) Charity Fund Supports Elite Athletes from The Education University of Hong Kong for the Fourth Consecutive Year
18:11 HKT/SGT
日清食品(香港)慈善基金連續第四年支持 香港教育大學精英運動員
17:57 HKT/SGT
智領未來彰顯科技領軍實力 中國電信榮膺「金紫荊」雙獎
17:23 HKT/SGT
高質量發展再上台階 中國核電摘「金紫荊」獎兩大獎項
17:12 HKT/SGT
加快創建世界一流上市發電公司 華能國際斬獲「金紫荊」獎兩項殊榮
17:00 HKT/SGT
建設世界一流綜合能源企業 華電國際摘「金紫荊」重磅獎項
16:50 HKT/SGT
中國通信服務榮膺「金紫荊獎」「卓越投資者關係管理上市公司」大獎
16:42 HKT/SGT
華潤飲料獲金紫荊獎「卓越上市公司」殊榮
16:27 HKT/SGT
中國電力再獲中國證券「金紫荊獎」兩項大獎
16:03 HKT/SGT
服務網絡強國和數字中國建設 中國聯通摘「金紫荊」兩大獎項
15:55 HKT/SGT
康哲藥業(867.HK/8A8.SG):磷酸蘆可替尼乳膏獲批 為中國批准的首款且唯一白癜風靶向藥
15:22 HKT/SGT
康哲药业(867.HK/8A8.SG):磷酸芦可替尼乳膏获批 为中国批准的首款且唯一白癜风靶向药
15:13 HKT/SGT
牧原股份招股:基石力挺 全球生豬產業龍頭企業稀缺價值十足
13:23 HKT/SGT
牧原股份招股:基石力挺 全球生猪产业龙头企业稀缺价值十足
13:17 HKT/SGT
腾讯等豪华股东阵容加持业绩增长亮眼 卓正医疗招股进行中
11:27 HKT/SGT
騰訊等豪華股東陣容加持業績增長亮眼 卓正醫療招股進行中
11:14 HKT/SGT
華富建業金融成為黃金贊助商 第三屆香港資本市場論壇2026圓滿舉行 把握新機遇 激發新動能 共創金融未來
10:44 HKT/SGT
华富建业金融成为黄金赞助商 第三届香港资本市场论坛2026圆满举行 把握新机遇 激发新动能 共创金融未来
10:32 HKT/SGT
Shoucheng Holdings' Robotics Portfolio Gains Visibility as AI and Automation Take the Stage at China's 2026 CMG New Year's Gala
09:00 HKT/SGT
松延動力登陸2026春晚!首程控股(0697.HK)作為第一大外部投資方 攜多家被投拿下機器人大滿貫
09:00 HKT/SGT
ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
08:00 HKT/SGT
Thursday, January 29, 2026
Formerra將供應福斯特醫療化合物至歐洲市場
22:00 HKT/SGT
Formerra将向欧洲供应福斯特医药化合物
22:00 HKT/SGT
Formerra to Supply Foster Medical Compounds in Europe
22:00 HKT/SGT
Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline
20:57 HKT/SGT
LEGENDARY HUMANITY, Listed on Gate.io, Launches RWA Market for Contemporary Artist Mago Nagasaka
19:40 HKT/SGT
LEGENDARY HUMANITY, Listed on Gate.io, Launches RWA Market for Contemporary Artist Mago Nagasaka
18:40 HKT/SGT
TCG.Zone Participates in a Historic Moment Surrounding the World's Only PSA 10 'Pikachu Illustrator'
18:30 HKT/SGT
牧原股份招股進行時:全產業鏈優勢助力行業領先 技術出海開拓新佈局
15:49 HKT/SGT
牧原股份招股进行时:全产业链优势助力行业领先 技术出海开拓新布局
15:28 HKT/SGT
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
15:15 HKT/SGT
Honda、2025年12月度 四輪車 生産・販売・輸出実績を発表
15:10 HKT/SGT
トヨタ、2025年 年間(1月-12月)販売・生産・輸出実績を発表
13:37 HKT/SGT
LEXUS、2025年の全世界販売実績を発表
13:35 HKT/SGT
Standard Chartered GBA Business Confidence Indices reveal steady business sentiment amid persistent external uncertainties
12:14 HKT/SGT
Quam Plus Financial Proudly Serves as Gold Sponsor to Capital Markets Forum 2026
11:52 HKT/SGT
华富建业金融成为黄金赞助商 第三届香港资本市场论坛2026圆满举行 把握新机遇 激发新动能 共创金融未来
11:45 HKT/SGT
華富建業金融成為黃金贊助商 第三屆香港資本市場論壇2026圓滿舉行 把握新機遇 激發新動能 共創金融未來
11:25 HKT/SGT
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
11:00 HKT/SGT
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
09:14 HKT/SGT
 ACN Search:
 
Asian Financial Forum kicks off 2026 as region's first major event of 2026
 
Daily Newsletter
Browse Press Releases
Press Releases by Industry »
Press Releases by Language »
Multimedia Press Releases »
Events newsroom »
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575